Immunotherapy is regarded as the most promising treatment for cancers. Various cancer
immunotherapies, including adoptive cellular immunotherapy, tumor vaccines, antibodies …

Monoclonal antibodies (mAb) are a major component of cancer therapy. In this review, we
summarize the different therapeutic mAbs that have been successfully developed against …

Monoclonal antibody therapies targeting tumour antigens drive cancer cell elimination in
large part by triggering macrophage phagocytosis of cancer cells,,,,,–. However, cancer cells …

Trastuzumab, a targeted anti-human epidermal-growth-factor receptor-2 (HER2) monoclonal
antibody, represents a mainstay in the treatment of HER2-positive (HER2+) breast cancer …

Simple Summary HER2-positive breast cancer (BC), which accounts for~ 20% of BC, is one
of the more aggressive and has the worst overall survival rate among them. These patients …

Several therapeutic monoclonal antibodies (mAbs), including those targeting epidermal
growth factor receptor, human epidermal growth factor receptor 2 (HER2), and CD20 …

The potential roles of breast cancer stem cells (BCSCs) in tumor initiation and recurrence
have been recognized for many decades. Due to their strong capacity for self-renewal and …

Immune checkpoint blockade (ICB) has revolutionized the treatment of cancer patients. The
main focus of ICB has been on reinvigorating the adaptive immune response, namely …

Although the efficacy of cancer radiotherapy (RT) can be enhanced by targeted
immunotherapy, the immunosuppressive factors induced by radiation on tumor cells remain …

Macrophages are one of the most abundant non‐malignant cells in the tumor
microenvironment, playing critical roles in mediating tumor immunity. As important innate …